ReviewWorld journal of gastrointestinal surgery2023
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.
Review in World journal of gastrointestinal surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07736495 (Evaluation of the Protective Effect of Alpha-Lipoic Acid Against 5-Fluorouracil-Induced Oral Mucositis in Colorectal Cancer Patients), which is not on this map. Cited by 167 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Protective Effect of Alpha-Lipoic Acid Against 5-Fluorouracil-Induced Oral Mucositis in Colorectal Cancer Patients
Who cites it
167 citing papers in PubMed, 2 syntheses or guidelines pooled it, 211 citations in OpenAlex.
- Inflammation and Colorectal Cancer: A Meta-Analysis of the Prognostic Significance of the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI).International journal of molecular sciences · 2024Pooled it
- The impact of pre-, pro- and synbiotics supplementation in colorectal cancer treatment: a systematic review.Frontiers in oncology · 2024Pooled it
- PRX5 as a critical driver of colorectal cancer stemness and tumorigenicity.Redox report : communications in free radical research · 2026Article
- Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Comparison of outcomes between robot-assisted and laparoscopic colorectal cancer surgery in patients with heart failure: a national readmission database analysis.Surgical endoscopy · 2026Article
- Silymarin and Zinc Oxide Nanoparticles Attenuate Experimental Colon Cancer in Rats Through Crosstalk of miR-192 and β-Catenin Pathways.Biomolecules · 2026Article
- Epigallocatechin-3-Gallate, the green tea polyphenol suppresses expression of CD31 and VEGFR2 and enhances the chemotherapeutic potential of irinotecan in AOM/DSS model of colorectal cancer in mice.Journal of the Egyptian National Cancer Institute · 2026Article
- PUM2 inhibits ferroptosis and enhances oxaliplatin resistance in COAD via the NEDD4L/NRF2 axis.Translational oncology · 2026Article
- HOXC9 transcriptionally activates NRP1 to promote cell malignant progression and immune evasion in colorectal cancer.Molecular genetics and genomics : MGG · 2026Article
- Distillers' Grains-Derived Bioactive Fraction Suppresses Colorectal Cancer Progression Through Modulation of Autophagy-Associated PI3K/AKT Signaling.Foods (Basel, Switzerland) · 2026Article
- From 2D to 3D Colorectal Cancer Patient-Derived Organoids (PDOs) and In Vivo Models: Copper(II) Complexes as Promising New Antitumor Agents.Journal of medicinal chemistry · 2026Article
- T1 colorectal cancer: determinants of lymph node metastasis, survival patterns, and risk-adapted management.Updates in surgery · 2026Review
- Live Biotherapeutic Products (LBPs) as Promising Microbiome-Based Medicines for Colorectal Cancer (CRC): Mechanistic Basis, Therapeutic Applications, and Translational Challenges.Probiotics and antimicrobial proteins · 2026Review
- Anticancer Potential of Streptomyces sp. Strain M12: Apoptosis Induction and Anti-Migratory Effects in Colorectal Cancer Cells.Applied biochemistry and biotechnology · 2026Article
- Apigenin 7-glucoside reprograms tumor metabolism and enhances immunotherapy efficacy in colorectal cancer via DLX5.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Prognostic Role of EMR1 in Lymph Nodes and Primary Tumors of Colon Cancer Patients.Advanced biology · 2026Article
- Single-cell analysis reveals crosstalk between TREM1-positive myeloid cells and cancer-associated fibroblasts in colorectal cancer progression.Journal of gastroenterology · 2026Article
- Review
- Evaluation of ornithogalum sigmoideum extract-induced cytotoxicity and expression of xenobiotic metabolism-related genes in HT29 cells.Molecular biology reports · 2026Article
- Oncolytic Vaccinia Virus-HSP70-shRNA Amplifies Viral Replication, ROS/Autophagy, and Immunity to Fight Colorectal Cancer.Cancer science · 2026Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) affects 1 in 23 males and 1 in 25 females, making it the third most common cancer. With roughly 608000 deaths worldwide, CRC accounts for 8% of all cancer-related deaths, making it the second most common cause of death due to cancer. Standard and conventional CRC treatments include surgical expurgation for resectable CRC and radiotherapy, chemotherapy, immunotherapy, and their combinational regimen for non-resectable CRC. Despite these tactics, nearly half of patients develop incurable recurring CRC. Cancer cells resist the effects of chemotherapeutic drugs in a variety of ways, including drug inactivation, drug influx and efflux modifications, and ATP-binding cassette transporter overexpression. These constraints necessitate the development of new target-specific therapeutic strategies. Emerging therapeutic approaches, such as targeted immune boosting therapies, non-coding RNA-based therapies, probiotics, natural products, oncolytic viral therapies, and biomarker-driven therapies, have shown promising results in preclinical and clinical studies. We tethered the entire evolutionary trends in the development of CRC treatments in this review and discussed the potential of new therapies and how they might be used in conjunction with conventional treatments as well as their advantages and drawbacks as future medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.